Damora Therapeutics, Inc.
About Damora Therapeutics, Inc.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$209.8M
- Total assets
- $260.5M
- Market cap
- $1.3B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.3B
- Shares outstanding
- 64.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $209.8M.
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Damora Therapeutics, Inc..
Write a review
News about Damora Therapeutics, Inc.
News & sentiment via Polygon.io
